Addendum: Low-value approvals and high prices might incentivize ineffective drug development

Vinay Prasad, Christopher McCabe, Sham Mailankody

Research output: Contribution to journalArticle

Abstract

In hindsight, we realize that we could have been more precise when using the terms 'profit' and 'revenue' in our article 'Low-value approvals and high prices might incentivize ineffective drug development'. Total revenue is defined as the receipts from sales1. Profit is defined as the excess of the receipts from sales over the spending of a business during any period1. Hence, profit is the total revenue minus the costs of a business, over a given period. Profit calculations include credit transactions and asset revaluations as well as cash transactions and changes in the value of real assets1.

Original languageEnglish (US)
Pages (from-to)787
Number of pages1
JournalNature Reviews Clinical Oncology
Volume15
Issue number12
DOIs
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Addendum: Low-value approvals and high prices might incentivize ineffective drug development'. Together they form a unique fingerprint.

  • Cite this